Almanac A1C

The Randle Cycle and Metabolic Inflexibility: When Your Body’s Fuel-Switching System Breaks Down

Posted

by

dr. Karunia Valeriani Japar

Table of Contents
Keywords: , , , , , , ,

Introduction

The glucose fatty acid cycle, first described by Philip Randle and colleagues in 1963, represents one of the most fundamental mechanisms in cellular metabolism [1]. This elegant system enables tissues to optimize fuel utilization based on substrate availability, hormonal signals, and metabolic demands. Under normal physiological conditions, tissues can efficiently switch between glucose oxidation during fed states and fatty acid oxidation during fasting periods, a capacity termed “metabolic flexibility” [2]. The clinical significance of this metabolic switching capacity has become increasingly apparent as rates of obesity, type 2 diabetes, and metabolic syndrome continue to rise globally. Disruption of the Randle cycle, leading to “metabolic inflexibility”, is now recognized as a central feature of insulin resistance and key driver of cardiometabolic disease progression [3,4].

At the cellular level, the Randle cycle operates through sophisticated regulatory networks centered on pyruvate dehydrogenase (PDH), the rate-limiting enzyme controlling glucose oxidation entry into citric acid cycle. When fatty acids are abundant, their oxidation produces acetyl-CoA, citrate, and NADH, which collectively inhibit key glycolytic enzymes and PDH activity through both allosteric mechanisms and covalent modification [5]. The regulation of PDH by pyruvate dehydrogenase kinases (PDKs) and phosphatases represents a critical control node. PDK4, in particular, is rapidly upregulated during fasting states and in response to fatty acid exposure, effectively shutting down glucose oxidation in favor of fat utilization [6]. This molecular switch allows tissues to preserve glucose for obligate glucose utilizing organs such as the brain and red blood cells.

In metabolic disease states, this finely tuned system becomes dysregulated. Chronic exposure to elevated free fatty acid oxidation pathways and suppression of glucose utilization [7]. This metabolic inflexibility creates a cascade of metabolic dysfunction including insulin resistance, ectopic fat accumulation, and inflammatory activation. Recent advances in metabolomics and systems biology have provided unprecedented insights into the complexity of metabolic inflexibility, revealing disrupted patterns of substrate utilization that can be detected years before the development of overt diabetes [8,9]. These findings have opened new avenues for early intervention and precision medicine approaches to metabolic disease prevention and treatment.

Metabolic Inflexibility: Mechanisms and Pathophysiology

Defining Metabolic Inflexibility

Metabolic inflexibility encompasses the inability to appropriately modulate fuel oxidation in response to changing substrate availability and physiological conditions [10]. This dysfunction manifest across multiple levels:

  • Cellular Level: impaired mitochondrial substrate switching, altered enzyme activity patterns, and disrupted metabolic signaling cascades.
  • Tissue Level: Reduced capacity for coordinated metabolic responses across muscle, liver, and adipose tissue.
  • Systemic Level: Dysregulated whole body fuel homeostasis with persistent metabolite elevations and blunted responses to nutritional challenges.

Mechanistic Pathways of Dysfunction

Lipid Overflow and Ectopic Deposition

The adipose tissue serves as the body’s primary lipid buffer, storing excess energy during periods of caloric surplus and releasing fatty acids during energy demand. When this buffering capacity is overwhelmed, either through excessive caloric intake or genetic/ acquired limitations in adipose expandability, lipids “overflow” into non-adipose tissues [11].

This ectopic lipid accumulation in skeletal muscle, liver, and pancreas creates local lipotoxic environments that directly impair insulin signaling and glucose metabolism. In skeletal muscle, intramyocellular lipid accumulation interferes with insulin receptor signaling and GLUT4 translocation, reducing glucose uptake capacity [12]. Hepatic steatosis similarly impair hepatic insulin sensitivity and promotes glucose production, while pancreatic lipid infiltration contributes to beta-cell dysfunction [13].

Mitochondrial Substrate Competition and Congestion

At the mitochondrial level, metabolic inflexibility reflects altered substrate competition dynamics. In insulin-resistant states, mitochondria exhibit preferential fatty acid oxidation even in the presence of glucose, a phenomenon termed “metabolic rigidity” [14]. This substrate preference creates a state of “metabolic congestion” where fatty acid-derived metabolites accumulate and inhibit glucose oxidation pathways.

Studies using high-resolution respirometry in muscle biopsies from insulin-resistant individuals demonstrate impaired capacity for substrate switching, with persistent fatty acid oxidation and reduced glucose-stimulated respiration [15]. These findings suggest fundamental alterations in mitochondrial fuel selection mechanisms that extend beyond simple substrate availability.

Accumulation of Bioactive Lipid Intermediates

Incomplete fatty acid oxidation in metabolically inflexible states leads to accumulation of bioactive lipid species including diacylglycerols (DAGs), ceramides, and acylcarnitines [16]. These lipid intermediates function as signalling molecules that directly interfere with insulin action:

  • Diacylglycerols activate protein kinase C isoforms that phosphorylate and inhibit insulin receptor substrate proteins
  • Ceramides activate protein phosphatase 2A and inhibit Akt/PKB signalling
  • Acylcarnitines serve as markers of incomplete fatty acid oxidation and correrlate with insulin resistance severity

Systemic Metabolomic Signatures

Advanced metabolomics approaches have revealed characteristic patterns of metabolic inflexibility that can be detected in circulation. During oral glucose tolerance tests, metabolically inflexible individuals demonstrate:

  • Persistent Elevation of Fatty Acid Metabolites: Including medium and long-chain acylcarnitines, indicating incomplete suppression of fatty acid oxidation [17].
  • Branched-Chain Amino Acid Dysregulation: Elevated branched-chain amino acids (leucine, isoleucine, valine) and their metabolites, reflecting altered protein metabolism and mitochondrial dysfunction [18].
  • Impaired Ketone Body Dynamics: Dysregulated ketone production and utilization, suggesting disrupted hepatic and peripheral fuel sensing mechanisms [19].

These metabolomic signatures provide both mechanistic insights and potential biomarkers for assessing metabolic flexibility in clinical settings.

Figure 1.  Comparative analysis of metabolic flexibility versus inflexibility. Panel A shows fuel switching capacity over time, demonstrating impaired substrate utilization in metabolically inflexible states. Panel B illustrates tissue-specific insulin sensitivity differences. Panel C presents metabolomic response patterns during glucose challenge. Panel D compares clinical biomarkers between flexible and inflexible metabolic phenotypes.

Clinical Implications and Disease Association

Type 2 Diabetes: Central Role of Metabolic Inflexibility

Type 2 diabetes represents the most extensively studied condition associated with metabolic inflexibility. The progression from normal glucose tolerance to overt diabetes involves progressive deterioration of fuel switching capacity across multiple tissues [20]. Muscle Insulin Resistance: Skeletal muscle, responsible for the majority of insulin- stimulated glucose disposal, exhibits early and progressive metabolic inflexibility in diabetes development. Reduced capacity for glucose oxidation during insulin stimulation, combined with persistent fatty acid oxidation, contributes to postprandial hyperglycemia [21].

Hepatic Glucose Dysregulation: The liver’s role in glucose homeostasis becomes compromised as hepatic insulin sensitivity declines. Metabolic inflexibility manifests as continued hepatic glucose production despite elevated insulin levels, contributing to fasting hyperglycemia [22]. Pancreatic Beta-Cell Dysfunction: Chronic lipid exposure and metabolic inflexibility contribute to progressive beta-cell dysfunction through lipotoxicity and glucotoxicity mechanisms. The inability to appropriately modulate insulin secretion in response to changing metabolic conditions accelerates diabetes progression [23].

Non-Alcoholic Fatty Liver Disease (NAFLD)

NAFLD represents a hepatic manifestation of systemic metabolic inflexibility, with prevalence rates exceeding 30% in developed countries and strong associations with insulin resistance and metabolic syndrome [24]. Hepatic Substrate Selection Dysregulation: In NAFLD, the liver exhibits preferential fatty acid oxidation and reduced glucose utilization, perpetuating hepatic steatosis. This metabolic preference is mediated by altered expression of key metabolic enzymes and transcription factors including SREBP-1c and ChREBP [25].

Role of Organic Cation Transporter 1 (OCT1): Recent research has identified OCT1 as a critical regulator of hepatic thiamine uptake, which directly affects PDH activity and substrate selection. OCT1 dysfunction or genetic variants associated with reduced function contribute to hepatic metabolic inflexibility and NAFLD development [26]. Progression to NASH: The transition from simple steatosis to non-alcoholic steatohepatitis (NASH) involves inflammatory pathways that further impair metabolic flexibility. Endoplasmic reticulum stress, triggered by lipid accumulation, activates inflammatory cascades that perpetuate metabolic dysfunction [27].

Cardiovascular Disease and Diabetic Cardiomyopathy

The heart’s remarkable metabolic flexibility, normally switching between fatty acids and glucose based on workload and substrate availability, becomes compromised in diabetic cardiomyopathy [28].

Cardiac Metabolic Remodelling: In diabetes, the heart exhibits increased reliance on fatty acid oxidation with reduced glucose utilization capacity. This metabolic shift contributes to cardiac inefficiency, as fatty acid oxidation requires approximately 11% more oxygen per ATP molecule generated compared to glucose oxidation [29].

Energy Substrate Inflexibility: The inability to increase glucose oxidation during high workload conditions or ischemic stress contributes to cardiac dysfunction and increased susceptibility to heart failure [30].

Ketone Body Utilization: Altered ketone metabolism in the diabetic heart may represent both an adaptive response to metabolic stress and a contributor to cardiac dysfunction, depending on the metabolic context [31].

Obesity and Adipose Tissue Dysfunction

Adipose tissue dysfunction plays a central role in systemic metabolic inflexibility through impaired lipid buffering capacity and altered adipokine secretion [32].

Adipose Tissue Expandability: Individual differences in adipose tissue expandability determine the threshold for lipid overflow and ectopic fat deposition. Individuals with limited adipose expandability develop metabolic complications at lower BMI levels [33].

Inflammatory Activation: Chronic low-grade inflammation in expanded adipose tissue impairs normal metabolic regulation and promotes systemic insulin resistance through release of pro-inflammatory cytokines and free fatty acids [34].

Regional Fat Distribution: Visceral adiposity is particularly associated with metabolic inflexibility compared to subcutaneous fat, due to direct portal circulation drainage and distinct metabolic characteristics [35]

Clinical Assessment and Biomarkers

Indirect Calorimetry: The gold standard for assessing metabolic flexibility  involves measuring respiratory quotient (RQ) changes in response to substrate challenges. Metabolically flexible individuals demonstrate appropriate RQ shifts, while inflexible individuals show blunted responses [36].

Metabolomic Profiling: Circulating metabolite patterns provide accessible biomarkers for metabolic flexibility assessment. Specific acylcarnitine profiles, amino acid patterns, and lipid species correlate with metabolic flexibility measures [37].

Insulin Clamp Studies: Hyperinsulinemic-euglycemic clamps combined with substrate tracers provide detailed assessment of tissue-specific metabolic flexibility, though their use is primarily limited to research settings [38].

Evidence-Based Interventions for Restoring Metabolic Flexibility

Evidence-based interventions for restoring metabolic flexibility, addressing disruptions in the Randle cycle and insulin resistance, center of lifestyle modification, structured exercise, targeted dietary strategies, and select pharmacological and nutraceutical agents. These interventions aim to reestablish the capacity to switch efficiently between lipid and glucose oxidation, restore insulin sensitivity, and ameliorate the metabolic sequelae of inflexibility.

Lifestyle and Dietary Interventions

Weight loss through caloric restriction, especially when combined with dietary patterns like the Mediterranean diet, significantly enhances metabolic flexibility and improves whole body insulin sensitivity, particularly in individuals with metabolic syndrome or type 2 diabetes. Mediterranean dietary patterns, high in monounsaturated fats, polyphenols, whole grains, and fiber, reduce hepatic steatosis, improve glucose uptake, and exert anti-inflammatory and antioxidant benefits, collectively reducing insulin resistance and supporting Randle cycle reactivations [2,39,40].

Exercise Interventions

Structured exercise training, particularly resistance and endurance modalities, restores both mitochondrial function and metabolic flexibility. Regular physical activity promotes greater fatty acid oxidation capacity, enhances skeletal muscle insulin mediated glucose uptake via increased GLUT4 translocation, and improves glycogen storage. Notably, exercise training can restore in vivo mitochondrial function and metabolic flexibility in type 2 diabetic patients, even when intramyocellular lipid storage is increased, thereby improving muscle insulin sensitivity [41,42,43,44].

Pharmacological Nutraceutical Approaches

Pharmacologic agents including metformin and GLP-1 receptor agonists, as well as SGLT2 inhibitors and DPP-4 inhibitors, offer additional improvement in insulin sensitivity and metabolic flexibility via complementary mechanisms such as modulation of hepatic glucose output and promotion of weight loss. Emerging data suggest supplementation with carnitine may also improve metabolic flexibility and insulin sensitivity in impaired glucose tolerance by enhancing mitochondrial fatty acid transport and oxidation [45].

Mechanistic Considerations and Targeting the Randle Cycle

Interventions that target metabolic inflexibility aim to correct the disrupted reciprocal regulation between fatty acid and glucose oxidation defined by the Randle cycle. Strategies increasing mitochondrial oxidative capacity mitigate lipid-induced impairments in glucose uptake, a hall mark of Randle cycle dysfunction. Exercise, in particular, interferes with lipid induced insulin resistance by enhancing key insulin signaling pathways and increasing pyruvate dehydrogenase activity, allowing for more effective switching between substrates [42,46 47].

Integrative Approaches

Combined approaches incorporating dietary modification, structured exercise, behavioral interventions, and, when necessary, targeted pharmacotherapy yield additive and often synergistic benefits in reversing insulin resistance and restoring metabolic flexibility. Regular monitoring with biomarkers of metabolic flexibility, such as respiratory quotient changes in response to nutritional or insulin challenges, can guide individualized intervention and track restoration of metabolic health [48,49].

Conclusion

Metabolic inflexibility, manifested as a disruption of the Randle cycle, is a pivotal contributor to the development and progression of insulin resistance and cardiometabolic diseases such as type 2 diabetes, NAFLD, and cardiovascular disorders. This pathological state is characterized by an impaired capacity to switch between glucose and fatty acid oxidation in response to environmental and physiological cues. Key mechanistic pathways include mitochondrial substrate competition, accumulation of bioactive lipid intermediates, lipotoxicity, inflammation, and deranged metabolomic signatures.

Addressing metabolic inflexibility requires an integrative, evidence-based approach. Lifestyle interventions such as caloric restriction, the adoption of Mediterranean or other nutrient-rich diets, and regular exercise (aerobic, resistance, and high-intensity modalities) consistently restore metabolic flexibility and enhance insulin sensitivity. Pharmacological agents like metformin, GLP-1 receptor agonists, SGLT2 inhibitors, and targeted nutraceuticals such as carnitine also show promise. Importantly, early detection through metabolomic profiling and personalized interventions can effectively halt progression toward overt metabolic disease.

Effective management and restoration of metabolic flexibility depend on tailoring interventions to individual risk factors and ongoing monitoring using established biomarkers such as respiratory quotient and metabolomic patterns. As research advances, targeted therapies aimed at fuel selection and metabolic signaling pathway may further optimize clinical outcomes in metabolic disease prevention and treatment.

References

  1. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1(7285):785-789.
  2. Smith RL, Soeters MR, Wüst RCI, Houtkooper RH. Metabolic flexibility as an adaptation to energy resources and requirements in health and disease. Endocrine Reviews. 2018;39(4): 489-517.
  3. Santo Colosimo, Sandip Kumar Mitra, Tirthankar Chaudhury, et al. Insulin resistance and metabolic flexibility as drivers of liver and cardiac disease in T2DM. Diabetes Research and Clinical Practice. 2023;203:111016.
  4. Kelley DE, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes. 2000;49(5):677-683.
  5. Roden M, Bernroider E. Hepatic glucose metabolism in humans—it’s role in health and disease. Best Practice & Research Clinical Endocrinology & Metabolism. 2003;17(3): 365-383.
  6. Sugden MC, Holness MJ. Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs. American Journal of Physiology-Endocrinology and Metabolism. 2003; 284(5):E855-E862.
  7. Rudi Stinkens, Gijs H. Goossens, Johan W. E. Jocken, Ellen E. Blaak. Targeting fatty acid metabolism to improve glucose metabolism. Obesity Reviews. 2015;16 (9): 715-757.
  8. Giovanni Fanni, Jan W. Eriksson, Maria João Pereira. Several Metabolite Families Display Inflexibility during Glucose Challenge in Patients with Type 2 Diabetes: An Untargeted Metabolomics Study. Metabolites. 2023;13(1):131.
  9. Fiehn O, Garvey WT, Newman JW, et al. Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2 diabetic obese African-American women. PLOS ONE. 2010;5(12):e15234.
  10. Timothy M. Griffin, Kenneth M. Humphries, James S. Kinter, et al. Nutrient sensing and utilization: Getting to the heart of metabolic flexibility. Biochimie. 2016;124:74-83.
  11. Stefania Camastra, Ele Ferrannini. Role of anatomical location, cellular phenotype and perfusion of adipose tissue in intermediary metabolism: A narrative review. Reviews in Endocrine and Metabolic Disorders. 2022;23(1):75-95.
  12. Shulman GI. Cellular mechanisms of insulin resistance. Journal of Clinical Investigation. 2000;106(2):171-176.
  13. Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiological Reviews. 2018;98(4):2133-2223.
  14. Nicola Lai, Ciaran E. Fealy, Chinna M. Kummitha, et al. Mitochondrial Utilization of Competing Fuels Is Altered in Insulin Resistant Skeletal Muscle of Non-obese Rats (Goto-Kakizaki). Frontiers in Physiology. 2020;11:677.
  15. Phielix E, Schrauwen-Hinderling VB, Mensink M, et al. Lower intrinsic ADP- stimulated mitochondrial respiration underlies in vivo mitochondrial dysfunction in muscle of male type 2 diabetic patients. Diabetes. 2008;57(11):2943-2949.
  16. Summers SA. Ceramides in insulin resistance and lipotoxicity. Progress in Lipid Research. 2006;45(1):42-72.
  17. Adams SH, Hoppel CL, Lok KH, et al. Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid β-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. Journal of Nutrition. 2009;139(6):1073- 1081.
  18. Newgard CB, An J, Bain JR, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metabolism. 2009;9(4):311-326.
  19. Cotter DG, Schugar RC, Crawford PA. Ketone body metabolism and cardiovascular disease. American Journal of Physiology-Heart and Circulatory Physiology. 2013;304(8):H1060-H1076.
  20. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009;32(Suppl 2):S157-S163.
  21. Boden G, Chen X, Ruiz J, White JV , Rossetti L. Mechanisms of fatty acid-induced inhibition of glucose uptake. Journal of Clinical Investigation. 1994;93(6):2438-2446.
  22. Boden G, Cheung P, Stein TP, Kresge K, Mozzoli M. FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis. American Journal of Physiology-Endocrinology and Metabolism. 2002;283(1):E12-E19.
  23. Poitout V , Robertson RP. Glucolipotoxicity: fuel excess and β-cell dysfunction. Endocrine Reviews. 2008;29(3):351-366.
  24. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y , Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84.
  25. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. Journal of Clinical Investigation. 2005;115(5):1343-1351.
  26. Matteo Figliuzzi, Francesca Romana Prandi, Ines Fassina, et al. Organic cation transporter 1 (OCT1) modulates multiple cardiometabolic traits through effects on hepatic thiamine content. PLOS Biology. 2018;16(4):e2002907.
  27. Zhiyuan Fang, Wenwen Gao, Qianming Jiang, et al. Targeting IRE1α and PERK in the endoplasmic reticulum stress pathway attenuates fatty acid-induced insulin resistance in bovine hepatocytes. Journal of Dairy Science. 2022;105(7):6139-6152.
  28. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007;115(25):3213-3223.
  29. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiological Reviews. 2010;90(1):207-258.
  30. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions: potential for pharmacological interventions. Cardiovascular Research. 1997;33(2):243-257.
  31. Aubert G, Martin OJ, Horton JL, et al. The failing heart relies on ketone bodies as a fuel. Circulation. 2016;133(8):698-705.
  32. Virtue S, Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the metabolic syndrome–an allostatic perspective. Biochimica et Biophysica Acta. 2010;1801(3):338-349.
  33. Lotta LA, Gulati P, Day FR, et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nature Genetics. 2017;49(1):17-26.
  34. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860-867.
  35. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444(7121):881-887.
  36. Kelley DE, Goodpaster B, Wing RR, Simoneau JA. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. American Journal of Physiology. 1999;277(6):E1130-E1141.
  37. Koves TR, Ussher JR, Noland RC, et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metabolism. 2008;7(1):45-56.
  38. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. American Journal of Physiology. 1979;237(3):E214-E223.
  39. Li M, Chi X, Wang Y, Setrerrahmane S, Xie W, Xu H. Trends in Insulin resistance: Insights into Mechanisms and Therapeutic Strategy. Signal Transduction and Targeted Therapy. 2022 Jul 6;7(1):1–25.
  40. Mambrini SP, Grillo A, Colosimo S, Zarpellon F, Pozzi G, Furlan D, et al. Diet and physical exercise as key players to tackle MASLD through improvement of insulin resistance and metabolic flexibility. Frontiers in Nutrition. 2024 Aug 20;11.
  41. Ang JHC, Sun L, Foo SYR, Leow MKS, Vidal-Puig A, Fontana L, et al. Perspectives on whole body and tissue-specific metabolic flexibility and implications in cardiometabolic diseases. Cell Reports Medicine. 2025 Sep;6(9):102354.
  42. Pehmoller C, Brandt N, Birk JB, Hoeg LD, Sjoberg KA, Goodyear LJ, et al. Exercise Alleviates Lipid-Induced Insulin Resistance in Human Skeletal Muscle-Signaling Interaction at the Level of TBC1 Domain Family Member 4. Diabetes. 2012 Jul 30;61(11):2743–52.
  43. Goodpaster BH, Sparks LM. Metabolic Flexibility in Health and Disease. Cell Metabolism. 2017 May;25(5):1027–36.
  44. Meex RCR, Schrauwen-Hinderling VB, Moonen-Kornips E, Schaart G, Mensink M, Phielix E, et al. Restoration of Muscle Mitochondrial Function and Metabolic Flexibility in Type 2 Diabetes by Exercise Training Is Paralleled by Increased Myocellular Fat Storage and Improved Insulin Sensitivity. Diabetes. 2009 Dec 22;59(3):572–9.
  45. Bruls YM, de Ligt M, Lindeboom L, Phielix E, Havekes B, Schaart G, et al. Carnitine supplementation improves metabolic flexibility and skeletal muscle acetylcarnitine formation in volunteers with impaired glucose tolerance: A randomised controlled trial. EBioMedicine. 2019 Nov;49:318–30.
  46. Randle Cycle – an overview | ScienceDirect Topics [Internet]. www.sciencedirect.com. Available from: https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/randle-cycle
  47. Lee SH, Park SY, Choi CS. Insulin Resistance: from Mechanisms to Therapeutic Strategies. Diabetes & Metabolism Journal. 2021 Dec 30;46(1).
  48. Palmer BF, Clegg DJ. Metabolic Flexibility and Its Impact on Health Outcomes. Mayo Clinic Proceedings. 2022 Mar;97(4):761–76.
  49. Galgani JE, Moro C, Ravussin E. Metabolic flexibility and insulin resistance. American Journal of Physiology-Endocrinology and Metabolism. 2008 Nov;295(5):E1009–17.